Dynamics of CD4+ T-Cells and Neutralizing Antibody Responses to Three Consecutive Doses of Inactivated COVID-19 Vaccines in PLWH.

Background: Comprehensive characterization of safety and immune responses to vaccines is crucial for the prevention and treatment of COVID-19 among people living with HIV (PLWH). This study aimed to investigate the dynamic changes in SARS-CoV-2-specific CD4+ T-cell subsets and neutralizing antibody after three consecutive doses of inactivated COVID-19 vaccines (BBIBP-CorV) among PLWH. Methods: The blood samples were collected from 165 PLWH, including 66 PLWH in the 3-month interval between the second and third dose (cohort 1) and 99 PLWH in the 5-month interval (cohort 2). Blood collection for immunogenicity analysis was performed at 1-month post-2nd vaccination, pre-3rd vaccination, and within 2-month post-3rd vaccination. Wilcoxon matched-pairs signed-rank test was applied to compare the SARS-CoV-2-specific CD4+ T cell subsets and neutralizing antibody level at different time points. The relationship among CD4+ T-cells, Tregs subpopulations and SARS-CoV-2-specific neutralizing antibody level were evaluated with Spearman non-parametric correlation test. Results: No serious adverse reactions were found among PLWH. After two-dose or three-dose inactivated COVID-19 vaccination, the absolute counts of CD4+ T-cells and Tregs subpopulations (CD4+CD25HighCD127Low Tregs, CD45RA+ rTregs and CD45RO+ eTregs) increased in two cohorts. Satisfactory SARS-CoV-2-specific neutralizing antibody responses to the third-dose vaccination were found in two cohorts, including significantly enhanced neutralizing antibody level and high neutralizing antibody seroconversion rate. In addition, SARS-CoV-2-specific neutralizing antibody level were positively associated with the absolute counts of CD4+ T-cells and Tregs subpopulations as well as the frequency of CD45RO+ eTregs in PLWH after three doses of vaccinations. Conclusion: The three doses of inactivated COVID-19 vaccination were both safe and effective to increase SARS-CoV-2-specific CD4+ T-cells and neutralizing antibody in two PLWH cohorts with different inoculation intervals.

Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV

Introduction Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is an effective way of protecting individuals from severe coronavirus disease 2019 (COVID-19). However, immune responses to vaccination vary considerably. This study dynamically assessed the neutralizing antibody (NAb) responses to the third dose of the inactivated COVID-19 vaccine administered to people living with human immunodeficiency virus (HIV;PLWH) with different inoculation intervals. Methods A total of 171 participants were recruited: 63 PLWH were placed in cohort 1 (with 3-month interval between the second and third doses), while 95 PLWH were placed in cohort 2 (with 5-month interval between the second and third doses);13 individuals were enrolled as healthy controls (HCs). And risk factors associated with seroconversion failure after vaccination were identified via Cox regression analysis. Results At 6 months after the third vaccination, PLWH in cohort 2 had higher NAb levels (GMC: 64.59 vs 21.99, P < 0.0001) and seroconversion rate (68.42% vs 19.05%, P < 0.0001). A weaker neutralizing activity against the SARSCoV-2 Delta variant was observed (GMT: 3.38 and 3.63, P < 0.01) relative to the wildtype strain (GMT: 13.68 and 14.83) in both cohorts. None of the participants (including HCs or PLWH) could mount a NAb response against Omicron BA.5.2. In the risk model, independent risk factors for NAb seroconversion failure were the vaccination interval (hazed ration [HR]: 0.316, P < 0.001) and lymphocyte counts (HR: 0.409, P < 0.001). Additionally, PLWH who exhibited NAb seroconversion after vaccination had fewer initial COVID-19 symptoms when infected with Omicron. Discussion This study demonstrated that the third vaccination elicited better NAb responses in PLWH, when a longer interval was used between vaccinations. Since post-vaccination seroconversion reduced the number of symptoms induced by Omicron, efforts to protect PLWH with risk factors for NAb seroconversion failure may be needed during future Omicron surges. Clinical trial registration https://beta.clinicaltrials.gov/study/NCT05075070, identifier NCT05075070.

Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.

Introduction: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is an effective way of protecting individuals from severe coronavirus disease 2019 (COVID-19). However, immune responses to vaccination vary considerably. This study dynamically assessed the neutralizing antibody (NAb) responses to the third dose of the inactivated COVID-19 vaccine administered to people living with human immunodeficiency virus (HIV; PLWH) with different inoculation intervals. Methods: A total of 171 participants were recruited: 63 PLWH were placed in cohort 1 (with 3-month interval between the second and third doses), while 95 PLWH were placed in cohort 2 (with 5-month interval between the second and third doses); 13 individuals were enrolled as healthy controls (HCs). And risk factors associated with seroconversion failure after vaccination were identified via Cox regression analysis. Results: At 6 months after the third vaccination, PLWH in cohort 2 had higher NAb levels (GMC: 64.59 vs 21.99, P < 0.0001) and seroconversion rate (68.42% vs 19.05%, P < 0.0001). A weaker neutralizing activity against the SARSCoV-2 Delta variant was observed (GMT: 3.38 and 3.63, P < 0.01) relative to the wildtype strain (GMT: 13.68 and 14.83) in both cohorts. None of the participants (including HCs or PLWH) could mount a NAb response against Omicron BA.5.2. In the risk model, independent risk factors for NAb seroconversion failure were the vaccination interval (hazed ration [HR]: 0.316, P < 0.001) and lymphocyte counts (HR: 0.409, P < 0.001). Additionally, PLWH who exhibited NAb seroconversion after vaccination had fewer initial COVID-19 symptoms when infected with Omicron. Discussion: This study demonstrated that the third vaccination elicited better NAb responses in PLWH, when a longer interval was used between vaccinations. Since post-vaccination seroconversion reduced the number of symptoms induced by Omicron, efforts to protect PLWH with risk factors for NAb seroconversion failure may be needed during future Omicron surges. Clinical trial registration: https://beta.clinicaltrials.gov/study/NCT05075070, identifier NCT05075070.

Time and frequency dynamics of connectedness between cryptocurrencies and commodity markets

This paper analyses the time and frequency dynamics of connectedness between cryptocurrencies and commodity sectors. It supports that cryptocurrency plays a virtual character in the global financial markets. The total spillovers from cryptocurrencies to commodity markets alternate during the COVID-19 period. The time-frequency domain spillover results illustrate that both in the short-run and long-run, cryptocurrencies contribute to the system as the main transmitter in risk spillover. Besides, the net spillover alternatives with time in different frequencies. The portfolio results illustrate that the hedging effect of cryptocurrencies varies among commodity sectors before and after COVID-19. After COVID-19 the cryptocurrencies show a better hedging tool in our system, especially the hedging effect of cryptocurrencies on ENTR and PMTR sectors. Furthermore, investors need to take cryptocurrencies into the portfolio and adjust the weight of cryptocurrencies according to the alternative hedging effectiveness index, especially after COVID-19.

The Associations of COVID-19 Induced Anxiety, Related Knowledge and Protective Behavior.

On the last day of 2019, 44 pneumonia cases with unknown etiology were reported to the World Health Organization (WHO) Country Office of China. This was the first cluster of what would be defined later as coronavirus disease (COVID-19). A self-administered questionnaire with multiple-choice items was created in Microsoft Forms (Microsoft Corp. Redmond, WA. 2020). A 5-point Likert scale with ten items, where "1" refers to "Totally disagree" and "5" refers to "Totally agree," was developed to evaluate the anxiety induced by the COVID-19 outbreak highlighting the suggested sources of stress and anxious emotions, e.g., "When I or any family member go outside home during this COVID-19 outbreak I feel anxious". A 5-point Likert scale with 14 items, where "1" refers to "Not at all like me" and "5" refers to "Just like me," was developed to evaluate people's protective behaviors against coronavirus infection from 3 dimensions: Routine Protective Behaviors (RPB), Post-exposure Protective Behaviors (PPB), and Post-exposure Risky Behaviors (PRB). Items in RPB are aimed to measure individuals' protective behaviors in daily life when facing the epidemic. A multiple-choice scale of 12 items was developed to assess public awareness of COVID-19 as an emerging infectious disease. The primary objective of this work was to develop psychometrically sound scales to assess COVID-19 induced anxiety (CIAS), protective behaviors towards COVID-19 (PBCS), and COVID-19 related knowledge. The results indicated that COVID-19 induced the 6-item version of the CIAS can adequately measure anxiety level. Infectious disease outbreaks represent specific health-related crises that may impact people's emotions in different patterns according to their emerging nature. Therefore, the CIAS was designed to cover the potential anxiety sources for the general population during the COVID-19 outbreak.

The Associations of COVID-19 Induced Anxiety, Related Knowledge and Protective Behavior

On the last day of 2019, 44 pneumonia cases with unknown etiology were reported to the World Health Organization (WHO) Country Office of China. This was the first cluster of what would be defined later as coronavirus disease (COVID-19). A self-administered questionnaire with multiple-choice items was created in Microsoft Forms (Microsoft Corp. Redmond, WA. 2020). A 5-point Likert scale with ten items, where “1” refers to “Totally disagree” and “5” refers to “Totally agree,” was developed to evaluate the anxiety induced by the COVID-19 outbreak highlighting the suggested sources of stress and anxious emotions, e.g., “When I or any family member go outside home during this COVID-19 outbreak I feel anxious”. A 5-point Likert scale with 14 items, where “1” refers to “Not at all like me” and “5” refers to “Just like me,” was developed to evaluate people’s protective behaviors against coronavirus infection from 3 dimensions: Routine Protective Behaviors (RPB), Post-exposure Protective Behaviors (PPB), and Post-exposure Risky Behaviors (PRB). Items in RPB are aimed to measure individuals’ protective behaviors in daily life when facing the epidemic. A multiple-choice scale of 12 items was developed to assess public awareness of COVID-19 as an emerging infectious disease. The primary objective of this work was to develop psychometrically sound scales to assess COVID-19 induced anxiety (CIAS), protective behaviors towards COVID-19 (PBCS), and COVID-19 related knowledge. The results indicated that COVID-19 induced the 6-item version of the CIAS can adequately measure anxiety level. Infectious disease outbreaks represent specific health-related crises that may impact people’s emotions in different patterns according to their emerging nature. Therefore, the CIAS was designed to cover the potential anxiety sources for the general population during the COVID-19 outbreak.